

## 510 (K) SUMMARY

The Vitaflon™ Plus/VasculonPlus® intravascular catheters are substantially equivalent in design to the Vasculon 2 Intravenous cannula (K883415), the Critikon (Johnson & Johnson company), Optically Clear Radiopaque Catheter (Optiva) (K893546), JELCO™ catheter (K853701) and the Becton-Dickinson Insyte Artcath Arterial Catheterization Unit (K921845).

These catheters are for the same intended use and function and are indicated to gain access to the peripheral vein of the blood system for intravenous therapy, blood transfusion and pressure monitoring.

The Vitaflon/Vasculon Plus catheter is substantially equivalent in catheter material to the Burron Implantofix (K851293), the Optiva (K893546) Criticon and the Insyte (K921845) B & D.

J



OCT - 6 1994

Food and Drug Administration  
1390 Piccard Drive  
Rockville MD 20850

BOC Ohmeda AB  
c/o Mr. Jonathan S. Kahan  
Hogan & Hartson  
Columbia Square  
555 Thirteenth Street, NW  
Washington, D.C. 20004-1109

Re: K941417  
Vitaflon™ Plus/Vasculon® Plus  
Regulatory Class: II  
Product Code: FOZ  
Dated: July 1, 1994  
Received: July 18, 1994


Dear Mr. Kahan:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

This letter immediately will allow you to begin marketing your device as described in your 510(k) premarket notification. An FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market, but it does not mean that FDA approves your device. Therefore, you may not promote or in any way represent your device or its labeling as being approved by FDA. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), promotion, or advertising please contact the Office of Compliance, Promotion and Advertising Policy Staff (HFZ-300) at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at their toll free number (800) 638-2041 or at (301) 443-6597.

Sincerely yours,



Philip J. Phillips  
Acting Deputy Director  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

4